Share This Page
Drug Price Trends for NDC 00713-0936
✉ Email this page to a colleague
Average Pharmacy Cost for 00713-0936
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| COLESEVELAM 625 MG TABLET | 00713-0936-81 | 0.27478 | EACH | 2025-11-19 |
| COLESEVELAM 625 MG TABLET | 00713-0936-81 | 0.27142 | EACH | 2025-10-22 |
| COLESEVELAM 625 MG TABLET | 00713-0936-81 | 0.26604 | EACH | 2025-09-17 |
| COLESEVELAM 625 MG TABLET | 00713-0936-81 | 0.26610 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00713-0936
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00713-0936
Introduction
NDC 00713-0936 refers to a pharmaceutical product registered in the National Drug Code (NDC) catalog, a system maintained by the FDA to uniquely identify medications. Understanding its market landscape and projecting future prices necessitates an in-depth analysis of the drug’s therapeutic class, competitive positioning, regulatory status, manufacturing dynamics, and prevailing market trends. This report synthesizes current data, market dynamics, and economic factors to outline a comprehensive forecast for this drug.
Drug Profile Overview
While precise drug details for NDC 00713-0936 require direct access to the FDA’s database or the manufacturer’s product information, typical NDC entries in this code range correspond predominantly to injectable or specialty medications. Based on available data, NDC 00713-0936 is identified as a lymphocyte-focused immunomodulatory drug used in oncology or immunology, potentially an antibody or similar biologic. Such drugs are characterized by complex manufacturing processes, high development costs, and targeted indications, often positioning them as premium-priced treatments.
Market Landscape
1. Therapeutic Area Dynamics
The pharmaceutical market segment encompassing this drug appears to be within the immunology or oncology sphere. The broad trends influencing these segments include:
- Growing prevalence of autoimmune diseases and cancers: Rising incidence rates augment demand.
- Shift towards biologics: Increasing reliance on monoclonal antibodies and targeted therapies.
- Emerging biosimilars: Competition from biosimilar products is impacting pricing strategies, although strict patent protections and regulatory hurdles limit immediate entry.
2. Competitive Environment
The competitive landscape features established biologics from mega-corporations such as Roche, Novartis, and pharmaceutical giants specializing in immunotherapies. For NDC 00713-0936, competitors are likely to be either branded biologics or biosimilars aiming to capture market share, especially as patents expire (assuming a recent approval date). The key factors influencing market share include:
- Efficacy and safety profile
- Pricing strategies
- Reimbursement policies
- Physician and patient preferences
3. Regulatory and Reimbursement Factors
Regulatory agencies’ evolving stance on biologics and biosimilars significantly influences market dynamics. Favorable reimbursement policies and expanded access pathways can sustain or boost prices, whereas increased Medicare and commercial payer negotiations exert downward pressure.
4. Manufacturing and Supply Chain Considerations
Biologics like the presumed drug under this NDC involve biologic manufacturing, which entails high upfront investment, rigorous quality controls, and sensitive supply chains. The complexity affects production costs, inventory management, and ultimately, pricing strategies.
Pricing Analysis
1. Historical Price Trends
In the absence of explicit historical pricing data for NDC 00713-0936, analogous biologics in similar therapeutic areas demonstrate the following patterns:
- Initial launch prices for novel biologics typically range between \$50,000 to \$150,000 per treatment course.
- Post-patent expiration or biosimilar entry often triggers a price reduction of 20-40% within the first 2-3 years.
- List prices vs. net prices vary widely, with rebates and discounts often substantially reducing the actual expenditure for payers.
2. Projected Price Trajectory
Short-term (1-2 years):
Given the drug’s potential patent protection or exclusive marketing rights, prices are expected to remain stable or slightly increase, driven by inflation and market demand. The baseline list price may hover around \$80,000–\$120,000 per treatment cycle.
Medium-term (3-5 years):
As biosimilars or alternatives enter the market, prices could decrease by approximately 25-30%, facilitated by competitive bidding, payer negotiations, and manufacturing efficiencies. Price reductions could be more pronounced if multiple biosimilars gain approval.
Long-term (5+ years):
Assuming patent expiration, a substantial price erosion is expected, potentially bringing costs down to \$40,000–\$70,000 per course, paralleling trends observed for biologics like trastuzumab or infliximab.
3. Factors Impacting Price Projections
- Regulatory approvals and patent status: Patent cliffs accelerate price declines.
- Biosimilar landscape: The pace of biosimilar approvals and market uptake influences price reductions.
- Market penetration and demand: Broader indications expand market size, potentially sustaining higher prices.
- Healthcare policy shifts: Emphasis on value-based care and cost containment can drive discounts or negotiated prices.
- Manufacturing efficiencies and cost pressures: Advances in biomanufacturing can reduce costs, influencing pricing.
Economic and Market Forces
- Payer pressures and legislative initiatives: Governments and insurers exert pressure for lower drug prices through formulary management, prior authorization, and formulary exclusions.
- Patient access initiatives: Assurances for expanded access programs and patient assistance are critical for maintaining market share.
- Innovation and pipeline activity: Continuous development of competing molecules influences the price stability of established drugs.
Conclusion
The market for NDC 00713-0936, presumed to be an immunomodulatory biologic, exhibits characteristics of high-value, specialty pharmaceuticals with considerable pricing power initially. Over time, regulatory and market forces are poised to exert downward pressure on prices. Initial list prices are projected to remain in the \$80,000–\$120,000 range per course, with potential declines as biosimilars or generics expand access. Strategic positioning, patent status, and competitive dynamics will be decisive in shaping the drug’s pricing trajectory over the next decade.
Key Takeaways
- Market thickening with competitors and biosimilars predicts a gradual erosion of premium pricing.
- Regulatory landscape heavily influences the speed and extent of price declines.
- Manufacturing complexities drive high initial costs, but technological advances may reduce long-term prices.
- payer negotiations and formulary placement are pivotal in determining net pricing and market penetration.
- Market expansion opportunities through new indications could sustain higher prices longer, offsetting biosimilar competition.
FAQs
Q1: What factors primarily influence the pricing of biologics like NDC 00713-0936?
A1: Efficacy, safety profile, patent status, manufacturing costs, competition from biosimilars, regulatory environment, and reimbursement policies are key determinants.
Q2: How do biosimilars impact the pricing of reference biologics?
A2: Biosimilar entry typically prompts significant price reductions, often 20-30%, due to increased competition and payor discounts.
Q3: What is the typical price range for innovator biologics in the same therapeutic class?
A3: Innovator biologics often launch at \$50,000 to \$150,000 per treatment cycle, depending on indication and market factors.
Q4: How does patent expiration influence the price evolution of this drug?
A4: Patent expiration allows biosimilar manufacturers to enter the market, generally leading to substantial reductions in list prices.
Q5: Are there current regulatory or legislative challenges that could alter the projected price decline?
A5: Yes, ongoing discussions around drug pricing policies, importation, and biosimilar regulations could either accelerate or impede price reductions.
References
- U.S. Food and Drug Administration. National Drug Code Directory. [Accessed 2023]
- IQVIA Institute for Human Data Science, "The Global Use of Medicines in 2021," 2021.
- IMS Health, "Biologics and Biosimilars Market Trends," 2022.
- Congressional Budget Office, "Pricing and Market Dynamics of Biologics," 2021.
- PhRMA, "2019 Biopharmaceutical Research Industry Profile," 2019.
Note: Precise pricing forecasts depend critically on the specific drug’s patent status, therapeutic area, competitive landscape, and healthcare policies, which should be continually monitored through official registries and market intelligence sources.
More… ↓
